Skip to main content

Table 2 Postoperative nausea and vomiting in hospital and after discharge

From: Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial

  Control (n = 67) Ramosetron (n = 67) P value
Postoperative 0–0.5 h
 Nausea 9 (13%) 4 (6%) 0.144
 Vomiting 2 (3%) 0 (0%) 0.496
 Nausea, VNRS 8 (22) 3 (11) 0.110
 IV ramosetron 5 (8%) 1 (2%) 0.208
Postoperative 0.5–3 h
 Nausea 16 (24%) 17 (25%) 0.841
 Vomiting 1 (2%) 2 (3%) 1.000
 Nausea, VNRS 7 (18) 6 (13) 0.736
 IV ramosetron 3 (5%) 2 (3%) 1.000
 IV metoclopramide 2 (3%) 0 (0%) 0.496
Post-discharge 24 h
 Nausea 22 (33%) 9 (13%) 0.008
 Vomiting 1 (2%) 2 (3%) 1.000
 Nausea, VNRS 14 (23) 5 (16) 0.011
 Oral metoclopramide 12 (18%) 4 (6%) 0.033
 Oral metoclopramide (mg) 2.4 (5.8) 0.6 (2.4) 0.021
Post-discharge 24–48 h
 Nausea 9 (13%) 5 (8%) 0.259
 Vomiting 0 (0%) 1 (2%) 1.000
 Nausea, VNRS 5 (14) 4 (15) 0.673
 Oral metoclopramide 4 (6%) 1 (2%) 0.365
 Oral metoclopramide (mg) 0.9 (4.2) 0.1 (1.2) 0.162
 Patient satisfaction score 86 (16) 95 (9) <0.001
  1. Data are expressed as mean (SD) or number of the patients (proportion)
  2. VNRS Verbal numerical rating scale